Clinical Trial Update: Study Evaluating ReFacto AF in Severe Hemophilia A [Phase 3]

View source ↗

Summary

Phase 3 study evaluating ReFacto AF in severe Hemophilia A has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Refacto AF (Factor VIII, recombinant)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED